Patents by Inventor Liewei Wang

Liewei Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11122997
    Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 21, 2021
    Assignees: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke University
    Inventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
  • Publication number: 20210283101
    Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of USP7 polypeptide to increase the sensitivity of cancer cells (e.g., CD340+ cancer cells such as HER2+ cancer cells) to treatment with an inhibitor of a CD340 polypeptide (e.g., an inhibitor of a HER2 polypeptide) are provided. Methods and materials for using USP7 polypeptide inhibitors in combination with CD340 polypeptide inhibitors to treat cancer (e.g., HER2+ breast cancer that was refractory to trastuzumab alone treatment) are provided.
    Type: Application
    Filed: July 7, 2017
    Publication date: September 16, 2021
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Liewei Wang, Matthew P. Goetz, Judy C. Boughey, Jia Yu, Bo Qin
  • Patent number: 10815534
    Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 27, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
  • Publication number: 20190255154
    Abstract: This document provides methods and materials for using butyrylcholinesterases (BChE) to treat cancer (e.g., triple negative breast cancer or prostate cancer). For example, methods and materials for using nucleic acid vectors (e.g., viral vectors) to express BChE polypeptides under conditions that reduce the number of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) and/or reduce the growth rate of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) are provided.
    Type: Application
    Filed: September 15, 2017
    Publication date: August 22, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: William S. Brimijoin, Liewei Wang, Yang Gao, Ping Chen, Liyi Geng, Jia Yu, Judy C. Boughey, Matthew P. Goetz
  • Publication number: 20190194761
    Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.
    Type: Application
    Filed: August 22, 2017
    Publication date: June 27, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
  • Publication number: 20190189247
    Abstract: The present disclosure provides methods for accurately predicting the dynamics of symptom response to drugs or other interventions for the treatment of major depressive disorder or other psychological conditions. These methods can allow for a shortening of the time period necessary for the evaluation of a drug or other therapeutic intervention. These predictive methods are based on measured and/or self-reported symptom severity measures at two or more points in time. These measures are then discretized into symptom classes (e.g., low, moderate, severe) and the symptom classes are then applied to the predictive model to predict the progression of symptoms and/or the effectiveness of a drug or other therapeutic intervention.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicants: The Board of Trustees of the University of Illinois, Mayo Foundation for Medical Education and Research
    Inventors: Ravishankar K. Iyer, Arjun Prasanna Athreya, Richard Merle Weinshilboum, Liewei Wang, William Victor Bobo, Mark Andrew Frye
  • Patent number: 10220016
    Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: March 5, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
  • Publication number: 20180098722
    Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 12, 2018
    Applicants: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke University
    Inventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
  • Publication number: 20180021295
    Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.
    Type: Application
    Filed: February 17, 2016
    Publication date: January 25, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
  • Publication number: 20120021920
    Abstract: Materials and methods related to using biomarkers for prediction of response to radiation therapy.
    Type: Application
    Filed: April 1, 2010
    Publication date: January 26, 2012
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Liewei Wang, Richard M. Weinshilboum, Krishna Kalari, Brooke L. Fridley, Yu Xin Qin
  • Patent number: 7858306
    Abstract: Isolated HSD3B1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are HSD3B1 allozymes. Methods for determining whether a subject contains an HSD3B1 sequence variant also are provided.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: December 28, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Richard M. Weinshilboum, Linda L. Pelleymounter, Eric D. Wieben, Oreste Salavaggione, Liewei Wang
  • Publication number: 20100311606
    Abstract: Materials and methods for evaluating cellular response to therapeutic agents.
    Type: Application
    Filed: May 7, 2008
    Publication date: December 9, 2010
    Inventors: Liewei Wang, Richard M. Weinshilboum, Liang Li, Brooke L. Fridley, Krishna Kalari, Daniel Schaid, Matthew M. Ames
  • Patent number: 7485711
    Abstract: Isolated CYP19A1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as CYP19A1 allozymes. Methods for determining the aromatase status of an individual also are provided, as are methods for determining if a subject is predisposed to certain clinical conditions.
    Type: Grant
    Filed: August 16, 2005
    Date of Patent: February 3, 2009
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Richard M. Weinshilboum, Eric O. Wieben, Oreste Salavaggione, Araba A. Adjei, Linda Pelleymounter, Josefa Coronel, Liewei Wang, Bruce Eckloff, Daniel Schaid, Cynthia X. Ma
  • Publication number: 20090023136
    Abstract: Isolated HSD3B1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are HSD3B1 allozymes. Methods for determining whether a subject contains an HSD3B1 sequence variant also are provided.
    Type: Application
    Filed: July 7, 2006
    Publication date: January 22, 2009
    Inventors: Richard M. Weinshilboum, Linda L. Pelleymounter, Eric D. Wieben, Oreste Salavaggione, Liewei Wang
  • Publication number: 20070037177
    Abstract: Isolated CYP19A1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as CYP19A1 allozymes. Methods for determining the aromatase status of an individual also are provided, as are methods for determining if a subject is predisposed to certain clinical conditions.
    Type: Application
    Filed: August 16, 2005
    Publication date: February 15, 2007
    Inventors: Richard Weinshilboum, Eric Wieben, Oreste Salavaggione, Araba Adjei, Linda Pelleymounter, Josefa Coronel, Liewei Wang, Bruce Eckloff, Daniel Schaid, Cynthia Ma